Stem Cell ‘Living Bandage’ for Knee Injuries in Human Trials

A prototype version of the cell bandage was trialled in five patients, aged between 18 and 45, with white-zone meniscal tears. The trial received funding support from Innovate UK and the promising results have been published in the journal Stem Cells Translational Medicine.

The procedure involved taking stem cells, harvested from the patient’s own bone marrow, which were then grown for two weeks before being seeded onto a membrane scaffold that helps to deliver the cells into the injured site. The manufactured cell bandage was then surgically implanted into the middle of the tear and the cartilage was sewn up around the bandage to keep it in place.

All five patients had an intact meniscus 12 months post implantation. By 24 months, three of the five patients retained an intact meniscus and had returned to normal knee functionality whilst the other two patients required surgical removal of the damaged meniscus due to a new tear or return of symptoms.

Professor Anthony Hollander, formerly of Bristol and now Chair of Stem Cell Biology at the University of Liverpool and Founder and Chief Scientific Officer of Azellon, said: “The cell bandage trial results are very encouraging and offer a potential alternative to surgical removal that will repair the damaged tissue and restore full knee function.

“We are currently developing an enhanced version of the cell bandage using donor stem cells, which will reduce the cost of the procedure and remove the need for two operations.”

The cell bandage was produced by the Advanced Therapies Unit at the NHS Blood & Transplant facility in Speke, Liverpool and implanted into patients at Southmead Hospital in Bristol, under the supervision of Professor Ashley Blom, Head of Orthopaedic Surgery at the University of Bristol.

Professor Blom, from Bristol’s School of Clinical Sciences, commented: “The cell bandage offers an exciting potential new treatment option for surgeons that could particularly benefit younger patients and athletes by reducing the likelihood of early onset osteoarthritis after meniscectomy.”

A spokesperson for Innovate UK said: “Turning stem cell research into clinical and commercial reality requires close collaboration between businesses, universities, and Hospitals. It’s great to see this inter-disciplinary approach has led to such an exciting outcome from this first-in-human trial.”